Neurosense Therapeutics Ebitda Over Time
| NRSN Stock | USD 0.90 0.02 2.17% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Neurosense Therapeutics Performance and Neurosense Therapeutics Correlation. Neurosense |
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Neurosense Therapeutics. If investors know Neurosense will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Neurosense Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.65) | Return On Assets (1.51) | Return On Equity (4.95) |
The market value of Neurosense Therapeutics is measured differently than its book value, which is the value of Neurosense that is recorded on the company's balance sheet. Investors also form their own opinion of Neurosense Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Neurosense Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Neurosense Therapeutics' market value can be influenced by many factors that don't directly affect Neurosense Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Neurosense Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Neurosense Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Neurosense Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Cross Equities Ebitda Analysis
Compare Neurosense Therapeutics and related stocks such as Quoin Pharmaceuticals, Revelation Biosciences, and Hillstream Biopharma Ebitda Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| QNRX | 15.3 M | 15.3 M | 15.3 M | 15.3 M | 15.3 M | 15.3 M | 15.3 M | 10.2 M | 15.3 M | (1.5 M) | (2 M) | (21.4 M) | (8.7 M) | (9.3 M) | (8.8 M) |
| REVB | (3.6 K) | (3.6 K) | (3.6 K) | (3.6 K) | (3.6 K) | (3.6 K) | (3.6 K) | (3.6 K) | (3.6 K) | (3.6 K) | (145.5 K) | (11.9 M) | (10.8 M) | (95.2 K) | (100 K) |
| NRBO | (267 K) | (267 K) | (267 K) | (267 K) | (267 K) | (6.1 M) | (14.7 M) | (33.1 M) | (23 M) | (19.1 M) | (29.7 M) | (15.2 M) | (11.4 M) | (15.9 M) | (16.7 M) |
| VRAX | (648.8 K) | (648.8 K) | (648.8 K) | (648.8 K) | (648.8 K) | (648.8 K) | (648.8 K) | (648.8 K) | (648.8 K) | (648.8 K) | (644.5 K) | (750) | (5.4 M) | (6.6 M) | (6.3 M) |
| NTRB | (400) | (400) | (400) | (400) | (400) | (400) | (151.3 K) | 2.3 M | (3.3 M) | (1.9 M) | (2.5 M) | (5.7 M) | (4.1 M) | (5.1 M) | (4.9 M) |
| LGVN | (5.6 M) | (5.6 M) | (5.6 M) | (5.6 M) | (5.6 M) | (5.6 M) | (5.6 M) | (5.6 M) | (5.6 M) | (2.2 M) | (2.9 M) | (16.2 M) | (17.1 M) | (20.1 M) | (19.1 M) |
| RNXT | (3.8 M) | (3.8 M) | (3.8 M) | (3.8 M) | (3.8 M) | (3.8 M) | (3.8 M) | (3.8 M) | (3.8 M) | (3.8 M) | (3.2 M) | (5.7 M) | (9.9 M) | (11.4 M) | (10.8 M) |
| KPRX | (5.8 M) | (5.8 M) | (5.8 M) | (3.1 M) | (2.5 M) | (6.7 M) | (13.3 M) | (14.5 M) | (10.7 M) | (6.8 M) | (6.6 M) | (13.7 M) | (13.6 M) | (12.4 M) | (13 M) |
| ALLR | (10.1 M) | (10.1 M) | (10.1 M) | (10.1 M) | (10.1 M) | (10.1 M) | (10.1 M) | (10.1 M) | (10.1 M) | (10.1 M) | (6 M) | (25.9 M) | (17.2 M) | (12.1 M) | (12.7 M) |
| BDRX | (3.8 M) | (3.8 M) | (3.8 M) | (4.3 M) | (7.4 M) | (9.4 M) | (5.3 M) | (10.6 M) | (10.7 M) | (10.3 M) | (22.2 M) | (5.7 M) | (7.4 M) | (7.2 M) | (7.5 M) |
Neurosense Therapeutics and related stocks such as Quoin Pharmaceuticals, Revelation Biosciences, and Hillstream Biopharma Ebitda description
My Equities
My Current Equities and Potential Positions
| Neurosense Therapeutics | NRSN |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Location | Israel |
| Exchange | NASDAQ Exchange |
USD 0.9
Check out Neurosense Therapeutics Performance and Neurosense Therapeutics Correlation. To learn how to invest in Neurosense Stock, please use our How to Invest in Neurosense Therapeutics guide.You can also try the Fundamental Analysis module to view fundamental data based on most recent published financial statements.
Neurosense Therapeutics technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.